This is an aggregated industry headline. Read the full story at Pharmaceutical Technology →
Japan’s FY26 price revision expands G1 repricing and drives price reduction
Japan’s latest NHI drug price revision for FY26 has now come into effect, with an average 4.02% drop in prices on a spending basis across 15,800 products.
By Pharmaceutical Technology
· May 8, 2026
· via Pharmaceutical Technology
Image: Pharmaceutical Technology
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
policyformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
PolicyFierceBiotech ↗
As an outbreak of Ebola in central Africa continues to worsen, the federal government has tapped a little-know…
PolicyBriefing
Eli Lilly’s lawsuit claims church-affiliated pharmacies and wholesalers defrauded it through fake rebate claim…
PolicySTAT News ↗
The Trump administration disclosed plans to reduce state directed payments even more, setting up a probable sh…